Lexpos News

The Department of Health and Social Care (DHSC) has today (28/11/2025) confirmed the following list of price concessions for November 2025: Please note: Community Pharmacy England has submitted price concession applications for a number of other medicines affected by pricing issues this month. We will issue further updates as soon as we hear back from the Department. [...]

The post November 2025 Price Concessions – 6th Update appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has confirmed that sufficient stock of Cefalexin 125mg/5ml oral suspension sugar free and Cefalexin 250mg/5ml oral suspension sugar free is now available to meet normal demand. As a result the Serious Shortage Protocol (SSP), SSP077 Cefalexin 125mg/5ml oral suspension sugar free and SSP078 Cefalexin 250mg/5ml oral suspension [...]

The post Expiry of SSP077 (Cefalexin 125mg/5ml oral suspension sugar free) & SSP078 (Cefalexin 250mg/5ml oral suspension sugar free) appeared first on Community Pharmacy England.

Following representations from Community Pharmacy England, the Department of Health and Social Care (DHSC) has re-determined that the following products will be granted special container status from 1 December 2025. Generic drug name (dm+d descriptor) Brand and/or manufacturer Pack Size Special container Salbutamol 2.5mg/2.5ml nebuliser liquid unit dose ampoules Teva UK Ltd 20 unit dose    [...]

The post 6 products re-classified as special containers from December 2025 appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has today (27/11/2025) confirmed the following list of price concessions for November 2025: Drug Pack size Price concession Betamethasone 500microgram soluble tablets sugar free 100 £46.65 Cyclizine 50mg/1ml solution for injection ampoules 5 £3.80 Dexamethasone 500microgram tablets 28 £1.87 Fenofibrate micronised 67mg capsules 90 £8.69 Lansoprazole 30mg orodispersible tablets [...]

The post November 2025 Price Concessions 5th Update appeared first on Community Pharmacy England.

From 1 December 2025, the use of the ‘FS’ prescriber endorsement has been extended to treatments used in the management of tuberculosis (TB) and latent TB infections, including the effects of TB and the adverse effects from TB treatment. Pharmacy teams should ensure that no prescription charge is levied for any items endorsed ‘FS’ by [...]

The post Use of ‘FS’ endorsement extended to Tuberculosis (TB) treatments appeared first on Community Pharmacy England.